Tomoyasu Otsuki1, Terumi Higuchi2, Toshio Yamazaki2, Erina Okawa2, Kazuyoshi Okada1, Masanori Abe3. 1. Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-chou, Itabashi-ku, Tokyo, 173-8610, Japan. 2. Department of Nephrology, Keiai Hospital, Tokyo, Japan. 3. Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-chou, Itabashi-ku, Tokyo, 173-8610, Japan. abe.masanori@nihon-u.ac.jp.
Abstract
OBJECTIVE: Pregabalin is a gamma aminobutyric acid derivative administered for neuropathic pain. It binds to α2δ subunits of voltage-dependent calcium channels, and inhibits calcium inflow of synapses and the release of excitatory neurotransmitters. This study investigated the efficacy and safety of pregabalin in patients with peripheral neuropathic pain undergoing maintenance hemodialysis. METHODS: This study was a prospective, open-label, single-arm, multi-center trial. Patients were treated with an initial dose of pregabalin at 25 mg; this was then increased up to a maximum of 150 mg depending on the patient during a 12-week study period. Visual Analog Scale, Eight-Item Short Form Health Survey (SF-8), and laboratory data were collected at baseline and the end of the study. RESULTS: A total of 45 patients with peripheral neuropathic pain were included, of whom 35 patients were analyzed. The final mean dose of pregabalin was 50.7 mg daily. Mean Visual Analog Scale scores significantly decreased from 52.4 mm at baseline to 34.1 mm at the end of the study (p < 0.0001). Scores for all eight categories of the SF-8 significantly increased compared with baseline (p < 0.05). Both physical and mental component summary scores of the SF-8 also significantly increased (p < 0.05). Ten patients were withdrawn from the study because of drowsiness, dizziness, and invalidity; however, no serious adverse drug reactions were recorded. CONCLUSIONS: If adverse effects are carefully monitored and the administered dosage prudently determined, pregabalin can be an effective treatment for peripheral neuropathic pain in patients undergoing hemodialysis. TRIAL REGISTRATION: UMIN000023117.
OBJECTIVE: Pregabalin is a gamma aminobutyric acid derivative administered for neuropathic pain. It binds to α2δ subunits of voltage-dependent calcium channels, and inhibits calcium inflow of synapses and the release of excitatory neurotransmitters. This study investigated the efficacy and safety of pregabalin in patients with peripheral neuropathic pain undergoing maintenance hemodialysis. METHODS: This study was a prospective, open-label, single-arm, multi-center trial. Patients were treated with an initial dose of pregabalin at 25 mg; this was then increased up to a maximum of 150 mg depending on the patient during a 12-week study period. Visual Analog Scale, Eight-Item Short Form Health Survey (SF-8), and laboratory data were collected at baseline and the end of the study. RESULTS: A total of 45 patients with peripheral neuropathic pain were included, of whom 35 patients were analyzed. The final mean dose of pregabalin was 50.7 mg daily. Mean Visual Analog Scale scores significantly decreased from 52.4 mm at baseline to 34.1 mm at the end of the study (p < 0.0001). Scores for all eight categories of the SF-8 significantly increased compared with baseline (p < 0.05). Both physical and mental component summary scores of the SF-8 also significantly increased (p < 0.05). Ten patients were withdrawn from the study because of drowsiness, dizziness, and invalidity; however, no serious adverse drug reactions were recorded. CONCLUSIONS: If adverse effects are carefully monitored and the administered dosage prudently determined, pregabalin can be an effective treatment for peripheral neuropathic pain in patients undergoing hemodialysis. TRIAL REGISTRATION: UMIN000023117.
Authors: Edward J Randinitis; Edward L Posvar; Christine W Alvey; Allen J Sedman; Jack A Cook; Howard N Bockbrader Journal: J Clin Pharmacol Date: 2003-03 Impact factor: 3.126
Authors: R Freynhagen; S Grond; G Schüpfer; A Hagebeuker; M Schmelz; D Ziegler; H-J Von Giesen; U Junker; K J Wagner; C Konrad Journal: Int J Clin Pract Date: 2007-09-24 Impact factor: 2.503
Authors: H Breivik; P C Borchgrevink; S M Allen; L A Rosseland; L Romundstad; E K Breivik Hals; G Kvarstein; A Stubhaug Journal: Br J Anaesth Date: 2008-05-16 Impact factor: 9.166